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Abstract
BACKGROUND—Activator Protein-1 (AP-1) family (cJun, JunB, JunD, cFos, FosB, Fra1, and 
Fra2) plays a central role in the transcriptional regulation of many genes that are associated with 
cell proliferation, differentiation, migration, metastasis, and survival. Many oncogenic signaling 
pathways converge at the AP-1 transcription complex. Transforming growth factor beta (TGF- ) is 
a multifunctional regulatory cytokine that regulates many aspects of cellular function, including 
cellular proliferation, differentiation, migration, apoptosis, adhesion, angiogenesis, immune 
surveillance, and survival.
METHODS—This study investigated, the role of FOS proteins in TGF-  signaling in prostate 
cancer cell proliferation, migration, and invasion. Steady state expression levels of FOS mRNA 
and proteins were determined using RT-PCR and western blotting analyses. DU145 and PC3 
prostate cancer cells were exposed to TGF- 1 at varying time and dosage, RT-PCR, western blot, 
and immunofluorescence analyses were used to determine TGF- 1 effect on FOS mRNA and 
protein expression levels as well as FosB subcellular localization. Transient silencing of FosB 
protein was used to determine its role in cell proliferation, migration, and invasion.
RESULTS—Our data show that FOS mRNA and proteins were differentially expressed in human 
prostate epithelial (RWPE-1) and prostate cancer cell lines (LNCaP, DU145, and PC3). TGF- 1
induced the expression of FosB at both the mRNA and protein levels in DU145 and PC3 cells, 
whereas cFos and Fra1 were unaffected. Immunofluorescence analysis showed an increase in the 
accumulation of FosB protein in the nucleus of PC3 cells after treatment with exogenous TGF- 1.
Selective knockdown of endogenous FosB by specific siRNA did not have any effect on cell 
proliferation in PC3 and DU145 cells. However, basal and TGF- 1- and EGF-induced cell 
migration was significantly reduced in DU145 and PC3 cells lacking endogenous FosB. TGF- 1-
and EGF-induced cell invasion were also significantly decreased after FosB knockdown in PC3 
cells.
CONCLUSION—Our data suggest that FosB is required for migration and invasion in prostate 
cancer cells. We also conclude that TGF- 1 effect on prostate cancer cell migration and invasion 
may be mediated through the induction of FosB.
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INTRODUCTION
Prostate cancer is the most diagnosed and the second leading cause of cancer deaths among 
American men. According to American Cancer Society, 180,896 men will be diagnosed and 
26,120 men will die of prostate cancer in US in 2016. Early stage prostate cancer which is 
localized in the prostate gland is treatable by surgery and radiation therapy and the prognosis 
in these patients is very good [1]. However, the prostate cancers in later stages of disease 
metastasize to other tissues and bone and pose a significant problem for treatment [1]. Death 
from prostate cancer results when cancer cells become metastatic after invading the lymph 
nodes and blood vessels and migrate to bone [2,3]. Current treatments for metastatic disease 
are hormonal therapy and chemotherapy. Hormonal therapies are based on inhibition of 
biosynthesis and/or action of androgens [4,5]. However, the cancer cells develop resistance 
to these treatments resulting in development of castration resistant or hormone refractory 
prostate cancers. There is no effective therapy for these cancers which are responsible for 
mortality in majority of patients.
In mammals, TGF-  is the prototype of a family of secreted polypeptide growth factors. To 
date, up to 33 TGF-  related genes have been identified which include TGF-  itself, bone 
morphogenic proteins (BMPs), activins/inhibin, growth and differentiation factors, nodal, 
and anti-müllerian hormone [6]. TGF-  signaling inhibits cell proliferation in a multitude of 
cell types, including normal endothelial, epithelial, hematopoietic, and neural cells, certain 
types of mesenchymal cells, and especially many primary cancer cells [7]. However, in a 
different cellular context, TGF-  can act as a tumor promoter because it is able to induce 
changes in transcriptional activities that re-program epithelial cells into mesenchymal cells, 
thereby facilitating tumor metastasis and invasion [6,8,9]. Previous studies from several 
laboratories have investigated the role of TGF-  secreted by the epithelial and stromal cells 
in the development and progression of prostate cancer [10–12]. Despite these studies, the 
molecular mechanisms and the intracellular effectors surrounding these differential effects of 
TGF- 1 during different stages of cancer progression are not well understood [13].
Activator protein-1 (AP-1) was one of the first transcription factors to be identified, but its 
physiological functions are still being unraveled [14]. AP-1 activity is induced by a plethora 
of physiological stimuli and environmental insults [14] such as growth factors, cytokines, 
tumor-promoters, and UV-irradiation [15]. AP-1 transcription factor consists of a variety of 
dimers composed primarily of members of the Fos and Jun families of proteins [16,17].
While the Fos proteins (FosB, cFos, Fra1, and Fra2) can only heterodimerize with members 
of Jun family, the Jun proteins (JunB, cJun, and JunD) can both homo- and heterodimerize 
with Fos members to form transcriptionally active complexes. AP-1 has been implicated in a 
variety of biological processes including cell differentation, proliferation, apoptosis, and 
oncogenic transformation [18]. AP-1 activity is modulated by interactions with other 
transcriptional regulators and is further controlled by upstream kinases that link AP-1 
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proteins to various signal transduction pathways [18]. AP-1 activity converts extra-cellular 
signals into changes in gene expression patterns through the binding of the AP-1 dimers to 
specific target sequences, the TPA-response element (TREs, TGAC/GTCA), in the promoter 
and enhancer regions of target genes [19,20]. Dimerization serves as a prerequisite for DNA 
binding as well as an enhancer of nuclear translocation. In vitro studies have determined 
that, in many situations, JUN–FOS heterodimers are more stable and have stronger DNA 
binding activities than JUN–JUN homo-dimers [21]. Although AP-1 proteins share a high 
level of sequence and function homology, they exhibit distinct expression patterns and differ 
in their transcriptional and biological activities [19]. Previous studies have shown that AP-1 
family proteins are differentially expressed in human cancers and have been suggested to 
play specific roles in cancer progression. The available evidence suggests higher 
proliferation rate, malignant transformation, and enhanced aggressiveness is accompanied 
by changes in AP-1 complex compositions [22]. For most processes, the precise composition 
of the AP-1 complexes and the critical target genes remain to be defined. Furthermore, the 
role of each individual AP-1 family member in prostate cancer development and progression 
and in TGF- 1 signaling have not been investigated. To address this, we have studied the 
expression of FOS family members in prostate epithelial and prostate cancer cells in vitro 
and utilized knockdown approaches to determine the role of individual FOS family members 
in prostate cancer cell proliferation, migration, and invasion.
MATERIALS AND METHODS
Chemical and Reagents
Recombinant human TGF- 1 (Catalog # HEK293 100-21) was purchased from Peprotech 
(Rocky Hill, NJ). The antibodies against FosB (Catalog# 2251S), cFos (Catalog # SC-52), 
Fra1 (Catalog # SC-605), and Fra2 (Catalog # SC-604) were purchased from Santa Cruz 
Biotechnology, Inc. (Dallas, TX). The anti- -Actin (Catalog # A5441) antibody was 
purchased from Sigma–Aldrich (St. Louis, MO). The anti-mouse and anti-rabbit 
immunoglobulins coupled with horseradish peroxidase (IgG-HRP) were obtained from 
Promega (Madison, WI). Cell lysis buffer was purchased from Cell Signaling (Danvers, 
MA). TRIzol was purchased from Invitrogen (Carlsbad, CA).
Human Prostate Cell Lines and Treatments
All cell lines were obtained from American Type Culture Collection. These include 
immortalized prostate luminal epithelial cell line (RWPE1) and prostate cancer cell lines 
(LNCaP, DU145, and PC3).
Expression of FOS family members—Prostate cells (RWPE1, LNCaP, DU145, and 
PC3) were cultured using established procedures [23–25]. To determine the basal expression 
of Fos mRNA and protein levels, RWPE1, LNCaP, DU145, and PC3 cells were seeded at a 
density 1.0 × 106 cells/dish in a 10 cm petri dish in the appropriate growth media and 
cultured at 37°C for 48 h. After 48 hr, the cells were washed with ice-cold phosphate 
buffered saline (PBS) and lyzed in cell lysis buffer containing 20 mM Tris–HCl (pH 7.5), 
150 mm NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 
1 mM -glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin, and 1× protease inhibitor 
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cocktail (Calbiochem, San Diego, CA). Protein concentrations were determined by the 
Lowry HS assay using the Bio-Rad DC Protein Assay kit (Bio-Rad Laboratories, Inc., 
Hercules, CA) according to the instructions provided by the manufacturer. The total RNAs 
were isolated from parallel experiments and were also used for RT-PCR as described below.
To determine the effects of TGF- 1 on FosB, cFos, Fra1, and Fra2 expression, prostate 
cancer cells were seeded in six-well plates at a density of 3.0 × 105 cells per well. Before 
each experiment DU145 and PC3 cells were incubated with media supplemented with 1% 
serum for 2 hr followed by treatment with different doses of TGF- 1 (0, 1, 5, 10 ng/ml) for 
specific time periods. RNA and proteins were isolated and quantified.
RNA Isolation, cDNA Synthesis, and RT-PCR
Total RNAs were isolated from prostate cells using TRIzol (Invitrogen) and the resulting 
RNA samples were quantified by optical density reading at 260 nm as described previously 
[26]. Total RNAs (2 μg) were reverse transcribed in a 50 μl reaction mixture containing 0.5 
mM dNTP (Fisher Scientific, Pittsburgh, PA), 0.5 mM dithiotreitol (Bio-Rad), 0.5 μg of 
oligo dT, and 400 U of M-MLV Reverse Transcriptase (Promega) at 37°C for 1.5 hr. The 
reaction was terminated by heating the samples at 65°C for 5 min and subsequently cooled 
to 4°C. PCR was performed to detect mRNA levels of FosB1, FosB2, cFos, Fra1, Fra2, and 
L-19. The PCR mixture was composed of 0.1 mM deoxynucleotide triphosphates, 0.5 U Taq 
DNA polymerase, 10× PCR Buffer with 3 mM MgCl2, and 25 pM of the specific primers in 
a total volume of 15 μl. Primer information and the size of specific amplicons for individual 
genes are shown in Table I. L-19 (a ribosomal protein) was used as a loading control. RNA 
samples processed without RT and PCR amplified were used as negative controls. 
Amplification was performed at 1, initial denaturant 94°C for 2 min; 2, 94°C for 15 sec; 3, 
58°C for 15 sec; 4, 72°C for 30 sec, 5, repeating steps two and four for 35 cycles for FosB1, 
FosB2, cFos, Fra1, Fra2, and L-19; 5, final extension 72°C for 2 min. The PCR products 
were separated on 1.0–2.0% agarose gels, and viewed under UV.
Western Blot Analysis
Total cellular proteins were prepared from different prostate cell lines and were analyzed by 
Western blot as described previously [26]. Briefly, cell lysates were mixed with Laemmeli's 
buffer (62.5 mM Tris, pH 6.8, 2% SDS, 5% –mercaptoethanol, and 10% glycerol). 
Individual samples containing 30–35 μg protein were subjected to SDS–PAGE in 10% gels 
and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore Corp., Bedford, 
MA). After blocking the membranes with 5% fat free milk in TBST (50 mM Tris, pH 7.5, 
containing 0.15 M NaCl, and 0.05% Tween–20) (cFos, Fra1, Fra2) or 5% bovine serum 
albumin (BSA) in TBST (FosB), for 1 hr at room temperature, the membranes were 
incubated with appropriate dilutions of specific primary antibodies (1:500 for FOS proteins 
and 1:5,000 for -actin) overnight at 4°C. After washing, the blots were incubated with 
secondary anti-rabbit (for FOS proteins) and anti-mouse (for -actin) IgG HRPs (1:20,000) 
for 1 hr. The blots were developed in ECL mixture (Thermo Fisher Scientific, Inc., 
Rockford, IL), and placed inside the Syngene PXi/PXi Touch darkroom imaging (high 
resolution, multi-application image analysis systems) (Frederick, MD) according to the 
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manufacturer's directions and the density of specific protein bands were determined using 
ImageJ image processing and analysis software and values were normalized using -actin.
Immunofluorescence of FosB
PC3 cells were seeded at a density of 8.0 × 104 cells/well into six-well plates containing 
sterile glass coverslips. The cells were incubated at 37°C and allowed to attach for 48 hr. 
The media were replaced with fresh media containing 1% FBS for 2 hr before treatment 
with TGF- 1 (10 ng/ml) for 4 hr. At the end of the treatment, media were aspirated and cells 
were fixed in 3.7% paraformaldehyde for 20 min at room temperature. The fixative was 
aspirated and cells were rinsed three times with 1.0 ml 1× PBS and permeabilized using 
0.1% Triton at room temperature. The cover slips were transferred to an aluminum wrapped 
20 cm Petri dish and outlined using a hydrophobic marker. The cells on the cover slips were 
blocked in blocking buffer containing 10% normal goat serum in 1× PBS for 1 hr. Blocking 
solution was aspirated and primary antibody (1:1,000) for FosB was added overnight at 4°C 
in 1× PBS with 2% normal goat serum. After washing five times in 1× PBS for 10 min each, 
secondary antibody containing green fluorochrome (Alexa Fluor 488 goat anti-rabbit IgG, 
Life Technologies, Carlsbad, CA) was added at room temperature for 1 hr in 1× PBS (light 
sensitive). After washing, DAPI (3 μg/ml) was added to cells for 20 min at room temperature 
to stain the nuclei. The cells were rinsed and the cover slips were then mounted on slides. 
Slides were kept at room temperature in the dark for 2 hr before viewing under inverted 
florescence microscope. Images were captured using 40× magnification with an Axiovision 
camera of a Carl Zeiss zoom inverted florescence microscope (Carl Zeiss, Thornwood, NY).
Transfection With FosB siRNA
To knockdown endogenous FosB expression, DU145 and PC3 cells were seeded in six-well 
plates at the density 1.5 × 105 cells per well in 1.0 ml antibiotic-free normal growth medium 
supplemented with 5% FBS. The cells were cultured at 37°C to 60–80% confluence. Control 
(scrambled) and FosB specific siRNAs were transfected into DU145 and PC3 cells 
according to the manufacturers’ instructions. Briefly, transfection complex were mixed 
together in a 1:1 ratio (2.5 μl for FosB) of siRNA to transfection reagent in 200 μl of 
antibiotic-free normal growth medium. The mixture was allowed to incubate at room 
temperature in the dark for 20 min. During this time the cells were washed once with 1 ml of 
siRNA transfection medium, after which the antibiotic-free medium was mixed with 1% 
FBS and added to the transfection reagent mixture. The transfection reagent siRNA duplex 
was overlaid onto the washed cells, and the cells were incubated overnight. The medium 
containing the transfection complex was replaced with complete medium containing 5% 
FBS and incubated for 48 hr. Cells were trypsinized (0.25% Trypsin/2.21 mM EDTA) for 1 
min and trypsin was neutralized with 3.0 ml of complete medium. Cells were centrifuged at 
1,000 RPM 4°C for 5 min and re-plated for biological assays. Western blot analyses were 
used to confirm FosB protein knockdown.
Cell Proliferation Assay
After transfection, the cells were counted and seeded into 96-well plates at a density of 5 × 
103 cells/well and treated with 10 ng/ml of TGF- 1 in the presence of 1% FBS for 72 hr. 
Cell viability was measured using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
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bromide (MTT) assay. MTT assays were performed using Cell Titer 96 Non-radioactive Cell 
proliferation assay (Promega) following the manufacturer's instructions.
Cell Migration Assay
After the transfections, in vitro cell migration assays were performed using 24-well 
transwell inserts (8 μm) as previously described [27,28]. Chemoattractant solutions were 
made by diluting TGF- 1 (10 ng/ml) or EGF (10 ng/ml) into MEM for DU145 and PC3 
cells supplemented with 0.2% BSA. The results were expressed as migration index defined 
as: the average number of cells per field for test substance/the average number of cells per 
field for the medium control. The experiments were conducted at least three times using 
independent cell preparations.
Cell Invasion Assay
After transfection, the invasive behavior of PC3 cells was measured using the BD BioCoat 
Matrigel Invasion inserts [29]. Cell culture inserts (VWR International, Bridgeport, NJ) were 
coated with 50 μl of 1:4 Matrigel/Medium dilutions (BD Sciences, San Jose, CA) and 
allowed to solidify at 37°C for 1 hr. Cells were resuspended (5.0 × 104 cells/ml) in MEM 
and 0.1% FBS and 500 μl of cell suspension was added to each insert. Chemoattractant 
solutions were made as described above with TGF- 1 and EGF into MEM supplemented 
with 0.1% FBS. Matrigel and non-invading cells were removed by scrubbing. Invading cells 
in the membrane were fixed in 3.7% paraformaldehyde and stained with DAPI. Pictures 
were taken from five different fields for average number of invading cells to be determined. 
The results were expressed as an invasive index defined as: the average number of cells per 
field for test substance/the average number of cells per field for the medium control. The 
experiments were conducted at least three times using independent cell preparations.
Statistical Analysis
All experiments were repeated at least three times. One way analysis of variance (ANOVA), 
Duncan's modified multiple range and Student–Newman–Keuls tests were employed to 
assess the significance of differences between treatment groups.
RESULTS
Expression of FOS Family Members in Prostate Cancer Cell Lines
We initially screened four human prostate cell lines, RWPE1 (normal prostate epithelial 
cells), LNCaP, DU145, and PC3 (prostate cancer cell lines) for expression of FOS family 
members. Levels of mRNA for FosB, cFos, Fra1, and Fra2 were determined using RT-PCR, 
with L-19 used as control (Fig. 1A). Fra2 mRNA was robust in all four cell lines, Fra1 and 
FosB mRNA were highly expressed in all cell lines except in LNCaP, which also had very 
low mRNA levels of cFos. ∆FosB was highly expressed in all cells with only moderate 
expression in RWPE1 cells (Fig. 1A). Western blot analyses was performed to determine the 
relative protein abundance of FosB, cFos, Fra1, and Fra2 (Fig. 1B). Fra1 protein levels were 
very low in all prostate cancer cell lines (LNCaP, DU145, and PC3) with slightly higher 
levels in RWPE1 cells (Fig. 1B). Fra2 protein levels were relatively high in RWPE1, DU145, 
and PC3 but were not detectable in LNCaP cells. cFos showed moderate expression in 
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RWPE1, DU145, and PC3 cells but was very low in LNCaP cells. FosB and ∆FosB protein 
levels were high in RWPE1 and PC3 cells but low to moderate in LNCaP and DU145 cells, 
respectively, (Fig. 1B).
TGF- 1 Effects on FOS Protein Expression and Nuclear Accumulation in Prostate Cancer 
Cells
DU145 and PC3 cells were treated with exogenous TGF- 1 (10 ng/ml) for 0, 1, 2, and 8 hr. 
TGF- 1 induced an increase in the mRNA levels of FosB in both cell lines but had little 
effect on the mRNA levels of the other FOS family members (Fig. 2A). At the protein levels, 
TGF- 1 induced an increase in the levels of FosB protein in both cell lines and an increase 
in Fra2 protein levels was observed only in PC3 cells. TGF- 1 had no effect on the levels of 
cFos and Fra1 in both cell lines (Fig. 2B). Spot densitometry analysis confirmed TGF- 1
effects on FosB and Fra2 protein levels in DU145 and PC3 cells in a time-dependent manner 
(Fig. 2C). TGF- 1 induction of FosB was dose dependent (Fig. 2D). Immunofluorescence of 
FosB in PC3 cells showed that treatment with TGF- 1 induced increased expression and 
nuclear localization of FosB (Fig. 2E).
FosB Knockdown Has No Effect on TGF- 1-Mediated Cell Proliferation But Abrogates TGF-
1 and EGF-Mediated Cell Migration and Invasion
Next, we determined the role of FosB in TGF- 1-induced cell proliferation, migration and 
invasion in prostate cancer cells. A transient knock down of FosB was carried out using 
siRNA specific to FosB, followed by a MTT proliferation (Fig. 3A and B), trans-well inserts 
migration assays (Fig. 4A and B), and matrigel invasion assays (Fig. 5). Knock down of 
FosB had no effect on cell proliferation in DU145 and PC3 cells (Fig. 3A and B); however, 
there was a significant decrease in cell migration (DU145, PC3) and cell invasion (PC3) in 
response to TGF- 1 and EGF in these cells (Fig. 4A, B and Fig. 5). Our data also suggests 
that FosB knockdown reduced both TGF- 1- and EGF-induced cell invasion but had no 
significant effect on the basal invasive potential of these cells (Fig. 5).
DISCUSSION
In this study, we demonstrate for the first time the role of Fos transcription factors in 
migration and invasion of prostate epithelial cancer cells. We performed two types of 
experiments: first, the effect of TGF- 1 on the Fos family expression levels were determined 
by western blot analysis using different doses and varying time of exposure to TGF- 1; the 
second part of this study, the influence of forced knock down of FosB transcription factor 
was used to determine the role of FosB on the proliferation, migration, and invasion of two 
prostate cancer cell lines of different proliferative, migratory, and invasive potential. The key 
findings in this study are that (i) TGF- 1 induces and increased expression of FosB in 
prostate epithelial cancer cells; (ii) FosB is essential for migration and invasion to occur in 
prostate cancer cells; and (iii) FosB is required for TGF- 1- and EGF-induced cell migration 
and invasion.
AP-1 family of transcription factors are a part of the complex immediate early genomic 
response of a variety of cells to transmembrane signaling agents [30]. Additional complexity 
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results from the variety of possible Jun dimers and the Jun–Fos heterodimers and from 
potential dimer formation between Jun or Fos and other leucine zipper proteins [30]. Jun and 
Fos proteins share extensive homology within the leucine zipper and basic domains. 
However, despite their homology, these proteins display different transcriptional activity 
[31]. The Fos proteins contribute distinct functions toward the activity of the AP-1 
heterodimers. For example, c-Fos can both activate and repress transcription [32], the full-
length FosB is a transcriptional activator [33] and a naturally occurring short form of FosB 
inhibits AP-1 transactivation [34]. The Fos-related antigens, Fra-1 and Fra-2 lack functional 
transactivation domains and are poor transcriptional activators [34]. We believed that an 
alteration in the composition of AP-1 either directly or indirectly regulates cell growth and 
motility, which in turn pushes the normal cell into pre-malignant or malignant state. 
Therefore, we analyzed the effect of TGF- 1 on Fos mRNA and protein expression in both 
normal as well as different prostate cancer cell lines. The most interesting observation was 
an immediate increase in FosB expression both at the mRNA and the protein levels in 
prostate cancer cells.
TGF-  super family signaling is well known as a key regulator of many biological processes 
[35] including differential effects on cell proliferation and migration in prostate cancer cells. 
These differential effects of TGF-  during different stages of cancer progression presumably 
depend on selective loss or acquisition of specific intracellular signals that are required to 
elicit different biological effects to TGF- . A loss of TGF-  receptors and/or Smad proteins 
has been shown to result in TGF-  resistance in cancer cells [12,23,36]. However, most 
cancer cells retain classical TGF-  signaling components throughout cancer progression but 
modify or recruit additional signaling pathways to exert novel or different biological effects 
[23]. Our data shows that TGF- 1 increases FosB expression in prostate cancer cells, which, 
in turn, mediates its effects on migration and invasion but does not play a role in TGF- 1
effects on cell proliferation. Thus TGF- 1 induction of FosB may represent a shift in 
intracellular signaling involved in the escape from inhibition of proliferation to the 
stimulation of more migratory and invasive behavior in advanced stages of prostate cancer.
While essential to normal development and homeostasis, the process of cellular migration is 
also a trait essential for metastasis. Enhanced migration is key across the metastatic cascade 
and is involved in the initial scattering of cells and migration from the primary tumor [37].
Numerous proteins and pathways have been implicated in altering the migratory potentials 
of cancer cells and therefore their aggressive nature. Given its essential role in cancer 
progression, treatments that inhibit cell migration or such proteins/pathways involved in 
enhancing cellular motility represent an attractive strategy for controlling meta-static 
dissemination [37]. Because Fra1 and Fra2 exhibit a lack of trans-activating domain as seen 
in cFos and FosB, they might exert inhibitory functions on tumor growth. However, recent 
data points to positive effects of Fra1 and partly Fra2, on tumor progression in many tumor 
types [20,38]. In contrast, to the bulk of data on the function of cFos and Fra1, far less is 
known about the role of FosB and its smaller splice variant ∆FosB which is often expressed 
more strongly than Fra1 in clinical cancer tissues [20,39]. Although, the Fos family of 
proteins has been extensively studied as immediate early genes, the role of FosB in cancer 
cell proliferation and migration has not been previously investigated. Our data shows that 
transient silencing of FosB with or without the presence of TGF- 1 has no effect on prostate 
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cancer cell proliferation but significantly reduces cell migration and invasion. Numerous 
studies have demonstrated that TGF- 1 induces the migration and invasion of prostate 
cancer cells; however, we show in this study that TGF- 1 is unable to induce prostate cancer 
cell migration and invasion without FosB. The data also suggests that epidermal growth 
factor (EGF), a potent mitogenic factor that plays an important role in the growth, 
proliferation and differentiation of numerous cell types is unable to induce migration and 
invasion in prostate cancer cells in the absence of FosB; further confirming that FosB does 
indeed have a major role in migration and invasion of prostate cancer cells. Thus the 
differences in migratory and invasive behavior observed in different stages of prostate cancer 
progression can be due to AP-1 specifically FosB activation. FosB may have a role in the 
aggressive phenotype observed in prostate cancer, thus inhibition of FosB activity may serve 
as a therapeutic tool in the management of prostate cancer.
CONCLUSIONS
In conclusion, our results obtained using human prostate cancer cell lines suggest that the 
transcription factor FosB may be an important regulator of TGF- 1 effects on migration and 
invasion in human prostate cancer cells. The further study of the role of FosB in prostate 
cancer carcinogenesis, especially in vivo, will be of great importance and will probably open 
new perspectives for therapy.
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FOS family basal expression. Steady state mRNA levels of FOS (FosB, cFos, Fra1, and 
Fra2) mRNA and protein expression. (A) Total RNA's were isolated and semi quantitative 
RT-PCR was performed to determine the mRNA levels of FosB, cFos, Fra1, and Fra2 in 
prostate cells. L-19 was used as an internal control. (B) Western blot analysis of FosB, cFos, 
Fra1, and Fra2 in prostate cells. -actin was used as a loading control.
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TGF- 1 effects on expression of FOS family members. (A) RT-PCR analysis of FosB, cFos, 
Fra1, and Fra2 mRNA levels in DU145 and PC3 prostate cancer cells after exposure to 
exogenous TGF- (10 ng/ml) for different times. (B) Western blot analysis of FosB, the 
FosB antibody used recognizes both full length FosB (higher molecular weight band) and 
∆FosB (lower molecular weight band), cFos, Fra1, and Fra2 protein levels DU145 and PC3 
prostate cancer cells after exposure to exogenous TGF- 1 (10 ng/ml) for different times. (C)
Band density analysis of FosB and Fra2 in DU145 and PC3 cells after treatment with TGF-
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1 for 2 and 8 hr. Each band density was normalized by density of -actin bands. Each bar 
represents the Mean ± SD from three independent experiments. “a and b” denote significant 
differences (P < 0.05) from untreated controls. (D) The Dose dependent effects of TGF- 1
on expression of FosB; Western blot analysis of FosB in prostate cancer cells DU145 and 
PC3 after treatment with varying concentrations of exogenous TGF- 1 (0, 1, 5, 10 ng/ml) 
for 4 hr. (E) Immunofluorescence, TGF- 1 activation of FosB in PC3. Cells were treated 
with exogenous TGF- 1 (10 ng/ml) for 0 and 4 hr.
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Effects of FosB knock down on TGF- 1-induced cell proliferation. DU145 (A) and PC3 (B)
cells were transfected with siRNA to transiently silence FosB followed by an in vitro 
proliferation assay.
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Effects of FosB knock down on cell migration. Prostate cancer cells DU145 (A) and PC3 
(B) were pretreated with siRNA against FosB for 72 hr. Western blots were used to confirm 
knock down of endogenous FosB (inserts). DU145 and PC3 cells were pretreated with 
siRNA against FosB, followed by treatment with 10 ng/ml of exogenous TGF- 1 and 10 
ng/ml EGF migratory behavior were measured using transwell insert migration assay. Each 
bar represents Mean ± SEM from three independent experiments. Different letters designate 
statistically significant (P < 0.05) differences among different treatments.
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Effects of FosB knock down on cell invasion. PC3 cells were pretreated with siRNA against 
FosB, followed by treatment with 10 ng/ml of exogenous TGF- 1 and 10 ng/ml EGF. 
Invasive behavior was measured using a matrigel in vitro invasion assay. Insert shows 
western blot used to confirm FosB knock down. Each bar represents Mean ± SEM from 
three independent experiments. Different letters designate statistically significant (P < 0.05) 
differences among different treatments.
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TABLE I
Gene-Specific Primers Used for RT-PCR Amplification
Gene Primers Sequence 5 -3 Product size (bp)
Full length FosB Sense AGCAGCAGCTAAATGCAGGA 131
Antisense GACGTTCCTTCTCCTTTTGGA
Delta FosB Sense CGAGAGGAGACGGAGACAGA 139
Antisense CTTCGTAGGGGATCTTGCAG
cFos Sense AGTGCCAACTTCATTCCCAC 265
Antisense CCCTTCGGATTCTCCTTTTC
Fra1 Sense TCTTCACCTACCCCAGCACTC 220
Antisense GCTGGAGTTGGATGTGGGATAC
Fra2 Sense CTGCTGGATCAAGTGCTTTCTC 150
Antisense GATTCAACAGACAACCAGGAATGG
L-19 Sense GAAATCGCCAATGCCAACTC 405
Antisense TCTTAGACCTGCGAGCCTCA
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